Physician profile
Fariborz Rezai
NPI 1942249313
$2,349,183.41
in general payments reported to CMS, 2019-2025
48 companies · $219K in 2025
The $219K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322K · 2020: $168K · 2021: $371K · 2022: $442K · 2023: $424K · 2024: $404K · 2025: $219K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $686K · Travel and Lodging: $94K · Consulting Fee: $87K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $85K · Honoraria: $68K · Food and Beverage: $26K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $686,460.89 |
| Travel and Lodging | $93,887.49 |
| Consulting Fee | $87,104.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $84,975.00 |
| Honoraria | $67,614.00 |
| Food and Beverage | $26,087.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $381,730.49 | 2020-2025 | Andexxa |
| Csl Behring | $280,814.56 | 2019-2025 | Kcentra |
| Gilead Sciences, INC. | $240,893.31 | 2021-2025 | Veklury |
| Janssen Pharmaceuticals, INC | $227,248.64 | 2019-2024 | Xarelto |
| Portola Pharmaceuticals, LLC | $145,602.47 | 2019-2020 | |
| Chiesi USA, INC. | $142,636.03 | 2021-2025 | Cleviprex, Kengreal |
| Allergan, INC. | $102,128.16 | 2019-2020 | |
| Shionogi INC | $99,942.96 | 2020-2025 | Fetroja |
| Mallinckrodt Hospital Products INC. | $96,913.72 | 2020-2025 | Terlivaz |
| Mylan Specialty L.P. | $88,974.85 | 2019-2024 | Yupelri, Yupelri |
| Alexion Pharmaceuticals, INC. | $86,468.81 | 2020-2024 | Ultomiris |
| Abbvie INC. | $65,022.78 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58,131.92 | 2019-2024 | Xifaxan, Relistor |
| La Jolla Pharmaceutical Company | $55,237.61 | 2019-2025 | Giapreza |
| Boston Scientific Corporation | $49,356.32 | 2020-2024 | Exalt Model D |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $44,795.79 | 2024-2025 | Balfaxar |
| Vapotherm INC | $44,603.70 | 2021-2023 | Vapotherm |
| Teleflex LLC | $28,268.38 | 2023-2025 | Arrow |
| Baxter Healthcare | $19,660.97 | 2019-2021 | |
| Verathon INC. | $16,812.61 | 2024-2025 | Video Laryngoscope, Bronchoscope |
| Merck Sharp & Dohme LLC | $14,994.33 | 2019-2023 | Recarbrio, Zerbaxa |
| Esperion Therapeutics, INC. | $11,078.27 | 2020-2021 | |
| Bioxcel Therapeutics, INC. | $9,332.31 | 2023 | Igalmi |
| Viatris Specialty LLC | $8,894.90 | 2025 | Yupelri |
| Mallinckrodt Enterprises LLC | $8,576.59 | 2019 | |
| Insmed, INC. | $7,939.06 | 2019 | |
| Melinta Therapeutics, LLC | $5,147.80 | 2022-2024 | Vabomere, Kimyrsa, Rezzayo |
| Acelrx Pharmaceuticals, INC. | $2,250.00 | 2020 | |
| Btg International INC. | $2,100.00 | 2025 | Aurlumyn |
| Edwards Lifesciences Corporation | $912.22 | 2020-2024 | |
| Becton, Dickinson and Company | $514.00 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $510.00 | 2020 | |
| Heron Therapeutics, INC. | $484.18 | 2020-2025 | Aponvie |
| Ambu INC. | $300.21 | 2025 | |
| Covidien Lp | $186.20 | 2019 | |
| Acacia Pharma INC | $118.61 | 2021 | |
| Cook Medical LLC | $114.90 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $103.18 | 2019 | |
| Bard Access Systems, INC. | $81.55 | 2019 | |
| Mindray Ds USA, INC. | $61.52 | 2022-2024 | Te7 Max, Te X |
| Ucb, INC. | $59.85 | 2020-2021 | |
| Masimo Corporation | $46.78 | 2022 | |
| Fennec Pharmaceuticals, INC. | $42.07 | 2023 | Pedmark |
| Invivyd INC | $31.63 | 2025 | Pemgarda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.94 | 2019 | |
| Philips North America LLC | $14.63 | 2022 | |
| Olympus America INC. | $13.60 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariborz Rezai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.